Fabrice Barlesi et al, 2024. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer Future oncology

Tina Cascone et al, 2025. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial Nature Medicine

Cascone et al, 2023. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase 2 NeoCOAST Platform Trial Cancer discovery

Herbst et al, 2022. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer Journal of Clinical Oncology

Thorbald van Hall et al, 2019. Monalizumab: inhibiting the novel immune checkpoint NKG2A Journal for Immunotherapy of Cancer

André, Vivier et al, 2018. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells Cell

Subscribe to Monalizumab